GSK's Anthony Rowe Puts Useful Quantum Chemistry at About 2,000 Logical Qubits Around 2030; Cleveland Clinic's Lara Jehi Tells Hospitals to Prepare Now
A pharma threshold and a hospital demonstration, reported 19 October 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
Anthony Rowe, who runs research data platforms, scientific computing and AI infrastructure at GSK, gave a drug company's answer to the oldest question in quantum computing: how big must the machine be before it helps? Speaking at the City Quantum & AI Summit earlier in October, he put the tentative threshold at about 2,000 logical qubits for chemistry problems he judges beyond conventional computers, with 2030 as the horizon on current hardware roadmaps.
On the same stage, Lara Jehi, chief research information officer at Cleveland Clinic, described how her hospital, IBM and the quantum software company Algorithmiq modelled a light-activated cancer drug with a hybrid quantum-classical workflow, work that won a $2 million prize from Wellcome Leap in April 2026. Her message to hospitals was to take part now, while the machines are still being designed.
Computer Weekly reported both talks on 19 October 2026. Read together, they give a hospital research office and a pharmaceutical buyer two useful reference points: a working demonstration at today's scale, and an industry estimate of the scale at which the chemistry starts to pay. The distance between the two is the planning problem.
Rowe's figure came from his earlier pilots in quantum chemistry, protein folding and optimisation before he joined GSK. According to Computer Weekly's account of the summit, he called the threshold tentative and acknowledged that better algorithms or hardware could change it. A logical qubit is an error-corrected unit built from many physical qubits, so 2,000 logical qubits implies a machine with a far larger number of physical ones.
The more candid part of his talk concerned people. Rowe had assembled a team to explore quantum applications, and its members asked to work on AI instead. "They all came to me and said, 'We'd rather work on problems in AI right now because we can be more successful.' So fine. I mean, we can pivot," he said, adding that the industry side has to keep generating a return on investment. He also argued that the computational chemists and physicists already working in life sciences have skills that would transfer to applied quantum computing as the hardware matures.
Zhao, Preskill and Huang's 8 April 2026 Paper Puts a 68,000-Cell Blood Dataset Benchmark Under 60 Logical Qubits: What a Quantum Memory Advantage Means for Hospital Genomics
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 8 April 2026 seven authors from Caltech, MIT, Google Quantum AI and the startup Oratomic, among them John Preskill and Hsin-Yuan Huang, posted a 144-page proof that, for a specified family of classification and dimension-reduction tasks under stated assumptions, a quantum computer of polylogarithmic size reaches a prediction performance that any classical machine would need exponentially more memory to match. The claim reached a wider readership on 11 September 2026, when WIRED Japan explained it to museum visitors as an advantage in size, not in speed.
The paper's medical test case is a genomics one. In a numerical benchmark on the expression profiles of 68,000 peripheral blood cells, the authors report that their method separates cell types and finds the main axis of variation with a calculated requirement of fewer than 60 logical qubits, where the classical methods chosen for comparison need four to six orders of magnitude more memory units. The proposed protocol draws random samples, processes each once and discards it; the benchmark reports performance and an estimated memory requirement, and it did not run that stream on a quantum machine. The advantage the authors prove is one of memory, not speed, and that distinction decides what a hospital genomics group should make of it.